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Members of the cyclic-AMP response-element binding protein (CREB) transcription factor family regulate the
expression of genes needed for long-term memory formation. Loss of Notch impairs long-term, but not short-
term, memory in ﬂies and mammals. We investigated if the Notch-1 (N1) exerts an effect on CREB-dependent
gene transcription. We observed that N1 inhibits CREB mediated activation of cyclic-AMP response element
(CRE) containing promoters in a γ-secretase-dependent manner. We went on to ﬁnd that the γ-cleaved N1
intracellular domain (N1ICD) sequesters nuclear CREB1α, inhibits cAMP/PKA-mediated neurite outgrowth and
represses the expression of speciﬁc CREB regulated genes associated with learning and memory in primary
cortical neurons. Similar transcriptional effects were observed with the N2ICD, N3ICD and N4ICDs. Together,
these observations indicate that the effects of Notch on learning and memory are, at least in part, via an effect
on CREB-regulated gene expression.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The “notched” wing phenotype was ﬁrst noted in the fruit ﬂy,
Drosophila melanogaster, 100 years ago. Subsequent molecular clon-
ing of the gene involved, named Notch, found it to encode a large
type-1 transmembrane receptor protein [1]. The gene is highly
conserved across species and in mammals there are four Notch receptor
homologs, Notch-1, -2, -3 and -4 [2]. The signalling pathway the Notch
receptors regulate plays numerous roles during development in many
tissues and is of particular importance in the nervous system where it
regulates neurogenesis and other cell fate decisions [3–6]. Notch
receptors are also expressed post-development in neurons of the adult
CNS where they participate in contact-dependent inhibition of neurite
growth [7,8].
It now emerges that Notch signalling also plays a role in memory
formation across species: In Drosophila [9,10] and in mice the loss of
Notch-1 (N1) [11,12] disrupts long-term memory formation (LTM) but
not short-term memory (STM). Notch signalling activity in the postnatal
mouse hippocampus was found to be dynamically regulated by ARC in
response to neuronal activity, with the deletion of N1 disrupting both
long-term potentiation (LTP) and long-term depression (LTD) [13], the
electrophysiological correlates of memory associated processes. Most
recently Drosophila Notch has been linked to the phosphorylation state
of the ﬂy homolog of the cyclic-AMP response element binding protein
(CREB), dCreB-17a [14], a transcription factor (TF) family intimately
linked with memory [15,16].
CREB TFs directly bindDNAand regulate genes involved in a range of
cellular processes in multiple tissues [17]. In the CNS CREB family TFs
regulate the expression of genes mediating stimulus-dependent,
long-term responses underlingneuronal survival and synaptic plasticity
and the expression of genes required for the formation of long-term
memory (LTM) [15,17,18].
In the “canonical” Notch signalling pathway, Notch receptors are
cleaved by γ-secretase, a presenilin-dependent multi-protein complex
that cleaves several type-1 transmembrane proteins to release the
intracellular portion of the receptor from the plasma membrane
[19]. γ-Secretase release of Notch receptor intracellular domains (ICDs)
permits them to translocate to the nucleus, where they regulate gene
transcription by binding with TFs of the CSL family. The mammalian
N1ICD also has been shown to interact with TFs from other signalling
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pathways, for example Lef-1 [20], FoxO1 [21], Smad1 [22] and, as we
demonstrated, p73 [23]. Given the promiscuous nature of the N1ICD
and the centrality of CREB to LTM formation, we asked if N1ICD might
interact with, and modulate, CREB-dependent gene transcription.
Speciﬁcally, we investigated if N1ICD modulates the expression of
neuronal genes involved in memory regulated by CREB.
We found that in multiple cell lines N1 antagonises CREB-regulated
gene transcription in a γ-secretase-dependent manner, that CREB1α
co-localises with N1ICD in the nucleus and that N1ICD and CREB directly
bind as shown by GST pull-down and chromatin immunoprecipitation
assays. In rodent primary neurons N1ICD also antagonises cAMP-
mediated neurite outgrowth and the neuronal expression of CREB-
regulated genes whose hippocampal expression is modulated by a fear-
conditioning paradigm of LTM. Finally, we found that this antagonism of
CREB-dependent gene transcription activity extends to all four
mammalian Notch ICDs.
2. Materials and methods
2.1. Cell lines, plasmids and reagents
HEK293a cells (an adherent clone of HEK293 cells) were purchased
from Quantum Biotechnologies (Montreal, QC, Canada). SH-SY5Y and
NT2 neuroblastoma cells were obtained from ECACC (UK). BD3 and
BD8 cells were a gift from Dorit Donoviel (Lexicon Genetics, Inc.,
Texas, USA). A human CREB1α cDNA, gifted by Dr Helen Hurst, was
subcloned into pcDNA3.1(+) (Invitrogen, Paisley, UK) and pGEX p6.1
(Amersham Biosciences, UK). A construct encoding the C-terminal 57
amino acids of the human β-amyloid precursor protein (APP) was
generated using the TOPO cloning system (Invitrogen). A human N4ICD
construct was generated from the Int3 cDNA, gifted by Dr U. Lendahl
(Karolinska Institute, Sweden). The CRE-Luc reporter and the α-isoform
of the murine catalytic subunit of PKA (PKA-Cα), were from Stratagene
(La Jolla, CA92037, USA). The following constructswere generously gifted
to us by: A-CREB, Dr David Ginty (Johns Hopkins School of Medicine,
Maryland, USA); VP16-CREB, Dr Boyoung Lee (Ohio State University,
USA); myc-His tagged human N1ICD, ΔTAD-N1ICD, ΔRA-N1ICD, N2ICD
and N3ICD, Dr Tom Kadesch (University of Pennsylvania, USA); ΔEN1,
Dr J. Aster (Brigham and Women's Hospital, USA); Human EGFP tagged
N1ICD (ICN-1), Dr S. Artavanis-Tsakonas (Yale, USA); 4xwt-CBF-Luc and
4xmut-CBF-Luc, Dr Gerry Weinmaster, (UCLA Medical School, USA).
2.2. Cell culture
All cells weremaintained in 5% CO2/air in a humidiﬁed incubator at 37
°C. HEK293a and NT2 cells were cultured in low glucose Dulbecco's mod-
iﬁed Eagle's medium (DMEM) – all culture media and supplements were
obtained from Invitrogen, Paisley, UK, unless otherwise stated – supple-
mented with 10% (v/v) foetal bovine serum (FBS) (Sera Laboratories
International, UK), 2 mM L-glutamine, 100 IU penicillin, and 100 mg/
ml streptomycin. SH-SY5Y neuroblastomas were grown in a 50/50
mix of F12/EMEM supplemented with 15% (v/v) FBS, 2 mM L-gluta-
mine, non-essential amino acids (Sigma, UK), 100 IU penicillin, and 100
mg/ml streptomycin. Rodent primary neurons were prepared and cul-
tured in Neurobasal media plus B27 supplement as previously described
[24].
2.3. Luciferase based reporter gene assays
Cells seeded in 48well plates were transfected with 100 ng of ﬁreﬂy
Luciferase based reporter DNA and 200 ng of each plasmid containing
the cDNA constructs being examined, using 1 μl FuGene6 per well
according to the manufacturer's instructions (Roche, Haywards Heath,
UK) and with 50 ng of phTK-Renilla luciferase (Promega, Southampton,
UK) to control for transfection efﬁciency. Empty vector DNAwas included
to maintain a constant DNA concentration, as needed. Fireﬂy and Renilla
luciferase activities were sequentially measured 24 h post transfection
using Promega Dual-Glo reagents and aWallac Trilux 1450 Luminometer
(PerkinElmer, UK). Fireﬂy values were divided by the Renilla values to
control for non-speciﬁc effects. Data for each set of three replica transfec-
tions were averaged, the control in each set normalized to 1 and the data
presented as fold increases (or percentage decreases) over control. All
experiments were performed in triplicate a minimum of three times.
2.4. Immunoﬂuorescence microscopy
Cells were transfected with ICN-1 independently or in combination
with CREB1α (200 ng of each) using FuGene 6 and ﬁxed in ice-cold
methanol 24 h after transfection then stained according to standard
protocols using anti-CREB 48H2 (Cell Signaling Technology NEB,
Hitchin, UK) and anAlexophor 594 nmconjugate anti-rabbit secondary.
Immunoﬂuorescence was imaged using a CoolSnap digital camera
(InterFocus Imaging, Linton, UK) attached to a Zeiss Axioscope (Zeiss,
Hertfordshire, UK).
2.5. Immunoblotting
Notch-1 proteins were immunoblotted according to standard
protocols using Santa Cruz sc-6014 goat anti-Notch-1 (1:1000) or sc-
789 mouse anti-myc (1:5000) followed by incubation with the corre-
sponding secondary antibody conjugated to 700 or 800 nM ﬂuorophors
and detected using an Odyssey infrared scanner (Li-Cor-Biosciences,
Cambridge, UK). Densitometry was performed using Licor Odyssey
software. Scanned blots were processed using PhotoShop (Adobe)
with all manipulations being applied to entire blots before cropping
for use in ﬁgures.
2.6. Chromatin Immunoprecipitation — ChIP
5 × 106 HEK293T cells, per condition, were transfected with CRE-Luc
(3 μg) and myc-His-N1ICD (6 μg) or pcDNA3.1C-myc-His (6 μg) using
FuGene6, ﬁxed 24 h post transfection with 1% formaldehyde and subse-
quently processed for ChIP according to the online protocol at http://
www.scbt.com/protocol_chromatin_immunoprecipitation_chip_assays.
html (Santa Cruz biotechnology). DNA was recovered from eluted
immune complexes byphenol–chloroformextraction and ethanol precip-
itation, thenused as input for PCR (80ng/reaction)withprimers spanning
the CRE sites within CRE-Luc.
2.7. Measurement of neurite growth
E19 rat cortical neurons were maintained in culture for 48 h then
transfected with pDsRed-Express C1 (Clontech, Hampshire, UK) in
combination with ICN-1, or empty vector, using Lipofectamine 2000
(Invitrogen). Five h post transfectionmediawere removed and replaced
with Neurobasal + B27. Neurons were treated 24 h post transfection
with 10 μM forskolin or the equivalent volume of vehicle (DMSO) for
24 h and ﬁxed with 4% (w/v) paraformaldehyde. Fluorescence micros-
copy was performed as above. The number and length of neurites was
determined using MetaMorph (Universal Imaging Corporation, USA).
Statistical signiﬁcance was determined by ANOVA and post hoc t-tests.
2.8. Fear conditioning
Three-month old C57BL/6J female mice were housed in groups of
four and maintained on a 12 h light/dark cycle with food and water ad
libitum. Experiments were undertaken in accordance with United
Kingdom Animals (Scientiﬁc Procedures) Act, 1986. Foreground
contextual fear conditioning (contextual fear conditioning without a
tone presentation) [25] was employed. Individual mice were placed into
the conditioning chamber (Med Associates Inc., VT, USA) and after 148 s
of exposure to the new environment the ﬁrst 2 s foot shock of 0.7 mA
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given, a second and third 2 s shockswere then administered at 90 s inter-
vals. The mouse was then removed after 30 s and returned to the home
cage. Animals were sacriﬁced at 0.5, 1 and 3 h after training. Naïve con-
trols were placed in the apparatus for the same time period as the trained
animals without receiving shocks (n=6 per condition). Hippocampi and
frontal cortices were rapidly dissected out, immediately frozen on dry ice
and stored at−80 °C for subsequent protein and RNA extractions.
2.9. Quantitative real time-PCR (qRT-PCR)
Total RNA was extracted using TRIzol (Invitrogen, UK) according
to the manufacturer's instructions, primed with random hexamers
and reverse transcribed according to the manufacturer's instructions
(PerkinElmer, UK). Gene speciﬁc primer sets were designed using
the Roche Universal ProbeLibrary Assay Design Centre (www.roche-
applied-science.com). SYBR green (Qiagen, Crawley, UK) qRT-PCR
reactions were performed in 96-well plates using an Opticon Disciple
PCR machine (Bio-Rad, London, UK). Succinate dehydrogenase A
(SDHA), 18S ribosomal RNA (18SRNA) and actin-γ-1 (Actg1) were
used as internal controls. Data were analyzed using Bio-Rad Chromo4
software. Data were pooled from 3 replica experiments and statistical
signiﬁcance determined by two-way ANOVA.
2.10. Forskolin treatment and infection of primary neurons with N1ICD
adenovirus
Mixed cortical/hippocampal neuronal cultures, prepared from E16
C57BL/6J embryos were seeded into 6-well plates at 1.5 × 106 cells/
well. After 5 days in culture cells were infected with an adenovirus
carrying EGFP tagged human N1ICD or with a control virus carrying β-
galactosidase at a MOI of 10 and treated 48 h later with 10 μM forskolin
or vehicle for 30, 60 and 90min. Total RNAwas then extracted and gene
expression determined by real time qRT-PCR.
3. Results
3.1. N1ICD inhibits CRE-driven transcriptional activity
To determine effects of the transcriptionally active portion of Notch-1,
the N1ICD, on CREB/CRE activity we employed a Luciferase based
Fig. 1.N1ICD represses CREB-dependent gene transcription. a)HEK293a, SH-SY5Y andNT2 cellswere transfectedwith a luciferase based CRE-reporter gene (CRE-Luc) and empty vectorDNAor
the myc-His N1ICD construct and 18 h post transfection treated with 10 μM forskolin (forsk) or 10 μM d,d-forskolin (dd-f) for 6 h, as indicated and luciferase activity subsequently measured.
b) HEK293a and SH-SY5Y cells were transiently transfected with CRE-Luc and PKA-Cα and N1ICD as indicated. Luciferase activity was measured 24 h post transfection. c) HEK293a cells were
transfectedwith CRE-Luc, N1ICD andCREB1α as indicated and luciferase activitymeasured 24hpost transfection. d) As c)with CREB1α being replaced by the constitutively active formof CREB,
VP16-CREB. e) As c) with CREB1α replaced by a dominant negative form of CREB, A-CREB. f) HEK293a cells were transfected with CRE-Luc, N1ICD and CREB1α as indicated, 18 h post
transfection cells were treated with forskolin for 6 h and luciferase activity subsequently measured. All data are pooled values from a minimum of three replica experiments. Statistical
signiﬁcance was determined by one-way ANOVA and post hoc t-testing.
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reporter-gene construct containing tandem repeats of the human CRE
sequence from the promoter region of the prototypic CREB regulated
gene, somatostatin (SST). HEK293a cells were transfected with this
construct, CRE-Luc, alone or in combination with myc-His-N1ICD. Next
day, transfected cells were treated with 10 μM forskolin or an inactive
analogue, 1,9-dideoxy-forskolin (dd-forskolin), for 6 h and Luciferase
activity measured. Forskolin treatment resulted in an ~33 fold increase
in CRE-Luc activity. Alone myc-His-N1ICD and dd-forskolin had minimal
effect upon reporter activity. However, in cells treated with forskolin
and receiving myc-His-N1ICD CRE-Luc activity was reduced by almost
70% (p b 0.02), Fig. 1a, left. To determine if this was cell-type dependent
we conducted replica experiments in two human neuron-like lines,
SH-SY5Y and NT2 cells, and also used a membrane permeable cAMP
analogue, dibutyryl-cAMP (db-cAMP), to activate PKA. In both cell lines
myc-His-N1ICD substantially reduced forskolin and db-cAMP induction
of CRE-Luc activity, Fig. 1a, middle and right panels. Next we examined
the effects of N1ICDwhen activating the reporter by transient exogenous
expression of the PKA catalytic subunit-α (PKA-Cα), which activates
endogenous CREB by phosphorylation at Serine133 [26]. N1ICD potently
(p b 0.01) antagonised PKA-Cα activation of CRE-Luc in all three cell
types, (HEK293a, SH-SY5Y), Fig. 1b, and in NT2 cells (not shown).
We next examined if N1ICD represses exogenously expressed CREB.
HEK293a cells were transfectedwith the CRE-Luc reporter and CREB1α.
In the absence of any agonistic stimulation, exogenous CREB1α activated
the reporter ~6 fold, whichwas inhibited by N1ICD to b3 fold (p b 0.01—
Fig. 1c). N1ICD also signiﬁcantly (p b 0.01) repressed the activity of a con-
stitutively active formof CREB, VP16-CREB, Fig. 1d.We then examined the
effects of N1ICD on a dominant negative form of CREB, A-CREB, which
alone repressed basal reporter activity by ~40%. Here and in the above
reporter assay experiments N1ICD gave slight repression of basal reporter
activity alone, and with A-CREB repressed basal activity further (Fig. 1e).
Finally, exogenously expressed CREB1α was activated with forskolin
(10 μM for 6 h), resulting in a greater than 60 fold activation, which
myc-His-N1ICD again potently antagonised (p b 0.01), Fig. 1f.
3.2. γ-Secretase cleavage is required for N1 inhibition of CRE-dependent
gene transcription
The Notch receptors undergo sequential proteolytic processing, the
ﬁnal cleavage, responsible for the release of the ICD, is performed by the
γ-secretase complex. The familial Alzheimer's disease (FAD) genes,
presenilin-1 (PSEN1) [27] and PSEN2 [28], are necessary components of
γ-secretase and inhibitors of γ-secretase have been shown to enhance
LTM [29]. We sought to determine if a membrane tethered form of
Notch-1, ΔEN1, which, due to the lack of the extracellular domain, is
constitutively cleaved by γ-secretase would affect CRE-dependent
gene transcription in the absence of γ-secretase activity either due to
pharmacological blockade or deletion of the PSEN genes. For the latter
genetic manipulation BD3 and BD8 mouse embryonic stem-cell cell
lines were employed [30]. BD3 cells have a single copy of PSEN1 and
no copies of PSEN2 (PSEN1+/−, PSEN2−/−). BD8 cells have no copies
either PSEN genes (PSEN1−/−, PSEN2−/−).
First we established the effects of manipulating γ-secretase
activity using a reporter gene for measuring canonical Notch transcrip-
tional activity. This CBF-1 reporter, 4 × wtCBF-1-Luc, or its control (4 ×
mutCBF-1-Luc) in which the CBF-1 sites are mutated, were transfected
into HEK293a cells alone or in conjunction with either N1ICD or ΔEN1.
Both N1ICD or ΔEN1 activated 4 × wtCBF-1-Luc (Fig. 2a, left hand bar
graph) but had little effect on the control reporter (data not shown).
Treatment with a γ-secretase inhibitor, GSI-1, at 1 μM for 6 h, virtually
abolished activation due to ΔEN1, but did not affect N1ICD activation.
In BD3 cells, harbouring one copy of PSEN1, both myc-His-N1ICD
andΔEN1 activated theCBF-1 reporter (Fig. 2a, centre bar graph),whilst
in BD8 cells lacking both PSEN1 and PSEN2, only N1ICD activated the
reporter (Fig. 2a right hand bar graph).
CRE-Luc reporter assays were then performed in HEK293a, BD3 and
BD8 cells with the inclusion of N1ICD and ΔEN1. Both N1ICD and ΔEN1
antagonised PKA-Cα activation of CRE-Luc in HEK293a cells (Fig. 2b)
and in the presence of the γ-secretase inhibitor N1ICD still signiﬁcantly
Fig. 2. Presenilin cleavage of Notch is required for repression of CRE-dependent gene
transcription. a) HEK293a, BD3 and BD8 cells were each transfected with the
“Notch” reporter gene, 4xCBF-Luc and ΔEN1 or N1ICD as indicated. 18 h post transfection
HEK293a cellswere treatedwith aγ-secretase inhibitor, GSI-1, at 1 μMfor 6 h as indicated.
Luciferase activity was measured 24 h post transfection. b) HEK293a cells were
transfected with CRE-Luc and PKA-Cα, ΔEN1 or N1ICD as indicated and treated with
GSI-1 18 h post transfection for 6 h. Luciferase activity was subsequently measured. c) BD3
and BD8 cells were transfected as in b) as indicated. Luciferase activity was measured 24 h
post transfection. All data are pooled values from a minimum of three replica experiments.
Statistical signiﬁcance was determined by one-way ANOVA and post hoc t-testing.
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repressed PKA-Cα activation of CRE-Luc, whilstΔEN1 had no signiﬁcant
effect on PKA-Cα activation— demonstrating that S3 (or γ-) cleavage of
N1 is necessary for its ability to repress CRE activity. This observation
was then conﬁrmed in cells lacking presenilins. In BD3 cells both
Notch constructs antagonised CRE-Luc activity, whilst in BD8 cells the
antagonistic effect of ΔEN1 was lost (Fig. 2c). These data indicate that
γ-cleavage and the subsequent nuclear translocation of N1ICD are re-
quired for N1 repression of CRE activity. However, the number of sub-
strates of γ-secretase is growing [19], certain of which, such as p75NTR
[31], have been shown to be associated with cAMP/PKA signalling [32]
andmemory [33]. As suchwe cannot rule out that other γ-secretase sub-
strates contribute to the effects we observe above.
3.3. The effect of N1ICD on CREB is direct
To determine if N1ICD impacts directly upon CRE-dependent gene
transcription or works through a transcriptional target gene, a time-
course analysis of its effect on the CRE-Luc reporter was carried out.
As can be seen in Fig. 3a the ability of myc-His-N1ICD to antagonise
PKA-Cα activation of CRE-Luc occurred at the earliest time point
at which an increase in reporter activity could be detected (4 h). The
absence of a time lag between reporter gene activation by PKA-Cα
and its antagonism by N1ICD indicates that N1ICD most likely exerts
its effect directly upon the cAMP/PKA/CREB pathway and not via the
induction of target genes, which in their turn antagonise CRE activity.
3.4. The N1ICD and CREB1α proteins associate in vitro
Nextwe sought to determine if theN1ICD andCREB proteins directly
interact by performing cell-free glutathione-S-transferase (GST) pull-
down binding assays. GST and GST-CREB1α recombinant proteins were
generated and puriﬁed using glutathione coated magnetic beads. Cell
lysates were generated from HEK293a cells transfected with myc-
His-N1ICD or empty vector and incubated overnight with equal
amounts of GST or GST-CREB1α bound beads. Binding proteins
were subjected to SDS-PAGE, immunoblotted and probed using an
antibody to the C-terminal of N1. GST-CREB1α-beads bound signiﬁ-
cantly (p b 0.01) greater amounts of myc-His-N1ICD compared to
the control GST-beads (Fig. 3b).
3.5. N1ICD sequesters CREB1α into subnuclear foci
We [34], and others [35], have previously shown that exogenously
expressed N1ICD protein forms discrete nuclear foci, which, it has
been suggested, may be the sites of “nuclear transcription factories”
[35]. If the N1ICD and CREB1α proteins associate in vivo, we predicted
that in the presence of exogenous N1ICD, CREB, which normally has a
diffuse nuclear staining pattern, would also be detectable in these foci
or alternatively that CREB might draw N1ICD out of the foci.
Fig. 3. N1ICD associates with CREB.a) Transcription time course analysis. HEK293a cells
were transfected with the CRE-Luc reporter and PKA-Cα or the reporter and PKA-Cα
and N1ICD as indicated. Luciferase activity was measured hourly over 12 h. No time lag
between activation by PKA-Cα and its repression by N1ICD was observed. b) Cell free
glutathione-S-transferase (GST) pull-down binding assay. HEK293a cells were transfected
with myc-His N1ICD or empty vector. Cell lysates were collected 24 h post transfection
and incubated with GST or a GST-CREB1α fusion protein coupled to agarose beads. Bound
proteins detected by immunoblottingwith an anti-Notch-1 antibody. GST-CREB1α bound
signiﬁcantlymoreN1ICD than didGST, p b 0.01. Statistical signiﬁcancewasdeterminedby
one-way ANOVA and post hoc t-testing. c) Sub-cellular co-localisation. HEK293a cells
were transfectedwith CREB1α and EGFP-tagged N1ICD separately and together as indicated
and examined by immunoﬂuorescencemicroscopy. Immuno-labelled CREB1αwas detected
with an anti-rabbit 594 nm ﬂuorophore conjugated antibody. Nuclei were labelled with
Hoescht 33342. Cells were imaged through blue, red and green ﬁlters. Scale bar = 10 μm.
CREB1α, which is normally diffuse throughout the nucleus, was found in N1ICD positive foci
when co-expressed with N1ICD. d) Chromatin immunoprecipitation. HEK293a cells were
transfected with CRE-Luc and myc-His N1ICD or CRE-Luc and empty vector. 24 h post
transfection cells were washed and ﬁxed and processed for chromatin immunoprecipitation
using an anti myc-tag antibody as described in the methods section. PCR, using primers
spanning the CRE elements of CRE-Luc, was performed on the immunoprecipitated
chromatin. An amplicon of the predicted size was generated from the anti-myc
immunoprecipitated chromatin in a dose dependentmanner indicatingN1ICD interactswith
the transcriptional complex bound to CRE sites.
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HEK293a cells were transfected with the EGFP-tagged N1ICD
construct and CREB1α, separately and in combination, and treated with
10 μM forskolin for 1 h prior to ﬁxation. When expressed individually
exogenous CREB1α immunostaining gave a diffuse staining pattern
throughout the nucleus (Fig. 3c top row, red channel) and EGFP-N1ICD
formed punctate nuclear foci (Fig. 3c centre row, green channel). An
identical staining pattern for N1ICD was seen with N1ICD-myc-His
when labelled with an anti-N1 C-terminal antibody or an anti-myc
antibody (data not shown), as previously reported [34]. When N1ICD
and CREB1α were co-expressed in cells, CREB immunostaining co-
localisedwith that of EGFP-N1ICD, CREB1α appearing to be sequestered
into the N1ICD positive foci (Fig. 3c bottom row, red channel). These
data further indicate that there is a protein–protein interaction between
N1ICD and CREB1α.
3.6. N1ICD interacts at CRE sites
To verify the interaction betweenN1ICD and CREB, and to determine
if it occurs at CRE sites, we performed chromatin immunoprecipitation
(ChIP). HEK293a cells were transfected with linearised CRE-Luc DNA
and myc-His-N1ICD or the empty pcDNA3.1 myc-His C vector, ﬁxed
24 h post transfection and processed. Fragmented chromatin was
immunoprecipitated with an anti-myc tag antibody and PCR performed
with primers spanning the CRE sites of the CRE-Luc reporter. PCR prod-
ucts of the correct sizewere generated in cells receiving themyc-tagged
N1ICD construct but not in cells receiving the empty vector, dose depen-
dently to amount of anti-myc antibody added (Fig. 3d). This observation
indicates that N1ICD interactswith CREBwhen bound to CRE containing
DNA. This interaction may be direct, or via other mutual binding part-
ners such as CBP or p300.
3.7. The TAD domain of Notch is needed for antagonism of CRE-dependent
gene transcription
We investigated which regions of N1ICD are involved in its interac-
tion with CREB by examining the effects of full-length and two myc-
His-N1ICD deletion constructs on CRE-Luc activity. The deletion con-
structs, ΔRA-N1ICD and ΔTAD-N1ICD, shown schematically in Fig. 4a,
were transfected alone and in combination with PKA-Cα and CRE-Luc
activitymeasured.ΔRA-N1ICD signiﬁcantly inhibited PKA-Cα activation
(p b 0.01)whilstΔTAD-N1ICDhad little effect (Fig. 4b), indicating that it
is the portion of N1ICD containing the TAD domain and the C-terminal
region beyond that is necessary for antagonism of CREB.
3.8. All four Notch isoforms antagonise CREB
To determine if the antagonistic effect upon CRE activitywas speciﬁc
to Notch1 (N1)we examined the effects of constructs encoding the ICDs
of N2, N3 and N4 upon PKA-Cα activation of the CRE-Luc reporter.
N2ICD, N3ICD and N4ICD were each able to signiﬁcantly (p b 0.01) in-
hibit CRE reporter activity. The most potent inhibition was consistently
observed with N2ICD (Fig. 4c).
Fig. 4. The TAD of N1ICD is needed for repression of CREB and N2, N3 and N4 ICDs also
repress CREB.a) Schematic of myc-His tagged, S3 cleaved, N1ICD and the two deletion
constructs, ΔRA-N1ICD and ΔTAD-N1ICD. RAM, Rbp-associated molecule domain; ANK,
ankyrin repeats; NLS, nuclear localisation signal; TAD, transactivation domain; OPA,
glutamine-rich region; PEST, proline (P), glutamic acid (E), serine (S) and threonine
(T) rich region; STR, serine/threnonine-rich region. Numbering corresponds to amino
acids in the full-length human N1 protein. b) HEK293a cells were transfected with
CRE-Luc and PKA-Cα (PKA), N1ICD, ΔRA-N1ICD and ΔTAD-N1ICD as indicated. Luciferase
activity was measured 24 h post transfection. c) HEK293a cells were transfected with
CRE-Luc and PKA-Cα, N1ICD, N2ICD, N3ICD and N4ICD as indicated. Luciferase activity
wasmeasured 24 h post transfection. All data are pooled values from aminimumof three
replica experiments. Statistical signiﬁcance was determined by one-way ANOVA and post
hoc t-testing.
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3.9. Notch represses PKA-dependent neurite growth
Notch1 and Notch2 inﬂuence the dendritic morphology of adult
neurons through CBF-1 and the HES family target genes [7,8]. This
does not rule out the possibility that the Notch ICDsmight also exert ef-
fects on other signalling pathways, such as the cAMP/PKA/CREB or CaM-
Kinase/CREB pathways, known to promote dendritic outgrowth in neu-
rons and neuronal-like cell lines [36–38]. As such we examined the ef-
fects of N1ICD on forskolin stimulated neurite outgrowth.
To do this primary rat cortical neurons were cultured for 1 day on
poly-D-lysine coated dishes, transfected with pDsRed and EGFP-N1ICD
or pDsRed and empty EGFP-vector. Cells were then treated with
10 μM forskolin or the inactive homolog for 24 h, ﬁxed andmorphology
examined by ﬂuorescence microscopy. Treatment of neurons with the
PKA inhibitor H-89 (20 μM) prevented forskolin induced increases
in neurite growth indicating that the effects of forskolin on neurite
outgrowth are PKA dependent, data not shown. However, some caution
needs to be taken when interpreting these data as H-89 has also been
shown to inhibit RhoA/ROCK [39], a regulator of actin cytoskeletal
dynamics and neuronal process formation.
Neurite length and number were measured. The longest process,
taken to be the axon,wasmeasured independently. Forskolin treatment
increased neurite and axonal length and caused a small reduction in
neurite number. Exogenously expressedN1ICD had the opposite effects,
increasing neurite number and decreasing neurite and axonal length. In
the presence of forskolin treatment N1ICD reduced neurite and axonal
length and neurite number to levels not signiﬁcantly different from
those of control values. Representative cells for each condition are
shown in Fig. 5a, data on process length and number are shown in
Fig. 5b. These observations demonstrate that cAMP/PKA-mediated
neurite outgrowth is antagonised by N1ICD. It also indicates that the
effects of N1ICD on neuronal morphology, increased neurite number
and reduced axonal length, are antagonised by PKA activation.
3.10. N1ICD inhibits the expression of genes associated with LTM
To determine if the effects of Notch on LTM formation in brain may
be due to inhibition of CRE activity we examined if N1ICD would
antagonise the transcription of CRE regulated genes whose expression
is modulated during memory formation. Three such genes were exam-
ined, thewell-characterised CREB target FOS [40], the orphannuclear re-
ceptor, NR4A1 [41], and serum/glucocorticoid regulated kinase-1, SGK1
[42,43].We veriﬁed that the expression of these three genes ismodulated
during memory formation in mouse hippocampus using a hippocampal-
dependent paradigm of LTM, contextual fear conditioning (CFC) [25].
Wild type C57/Black6mice (n=6)were subject to CFC and hippocampal
tissue collected from naïve mice and conditioned mice at 30, 60 and
180 min post conditioning. Total RNA was extracted and real time qRT-
PCR performed. The hippocampal expression of all three genes increased
following CFC. The expression of FOS and NR4A1 peaked at 30 min and
SGK1 at 60 post conditioning (data not shown). Next time-course
(30 min to 3 h) and dose–response (1 to 20 μM) studies with forskolin
were performed on E16 mouse primary hippocampal/cortical neurons
maintained in vitro for 7 d (7 d.i.v.). Total RNA was extracted and real
time qRT-PCR performed. Maximal FOS expression occurred at 30 min
with a 10 μM dose of forskolin (Fig. 6a).
Fig. 5.N1ICD represses forskolin induced neurite growth. a) E18 rat primary cortical neu-
rons were cultured for 24 h and transfected with pDsRed in combination with EGFP-
tagged N1ICD or empty vector. Post transfection, cells were treated with 10 μM forskolin
or vehicle for 24 h, then ﬁxed. DsRed labelled neurons were imaged and neurite length,
neurite number and axon lengthmeasured. Only cells with EGFP positive nucleiwere con-
sidered transfected by the EGFP-N1ICD construct. Representative cells from each condi-
tion are shown. b) Data obtained on neurite length, axon length and neurite number are
presented in tabular form and as bar charts. Statistical signiﬁcance was determined by
one-way ANOVA and post hoc t-testing.
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To examine the effects of N1ICD onneuronal gene expressionwe used
an EGFP-N1ICD adenovirus and a β-galactosidase adenovirus as control.
Transformation of cultured neurons with the control β-galactosidase
adenovirus at a multiplicity of infection (MOI) of 10 had little effect on
basal, or on forskolin induced expression levels of FOS (data not
shown). Cultured neurons were infected at 5 d.i.v. with either EGFP-
N1ICD or control adenovirus at a MOI of 10 and subsequently treated
48 h later with 10 μM forskolin for 30 min, 1 h and 3 h. The expression
of FOS, NR4A1 and SGK1 at the time points corresponding to their peak
induction post CFC was signiﬁcantly reduced in cells infected with
EGFP-N1ICD compared to cells infected with the control virus (Fig. 6b).
N1ICD thus represses the neuronal expression of endogenous CREB
regulated genes that have been implicated in LTM formation.
4. Discussion
Although Drosophila Notch [9,10] and murine Notch-1 [11,12] have
been found to be necessary for the proper establishment of LTM, the
molecular mechanism(s) through which Notch impacts on LTM
formation have not been determined. Here we present data obtained
through several different approaches that together strongly indicate
that the transcriptionally active portion of mammalian Notch 1, the
N1ICD, binds with CREB1α and exerts a repressive effect on CREB-
dependent gene transcription. The region of N1ICD involved in this inter-
action lies between amino acids 2094 and 2556 of humanNotch-1,which
contains the transactivation, OPA and PEST domains. Importantly, in
respect to LTM, we found that in primary neurons N1ICD represses the
transcription of hippocampal genes whose expression levels are
modulated during memory formation. Furthermore, we found that this
repressive effect of Notch extends to thewholemammalianNotch family,
i.e., Notch-2, -3 and -4 ICDs.
Heterozygous null mutations of CBF1, the canonical Notch pathway
TF, have similar effects on LTM as heterozygous null mutations of
Notch-1 [12], implying that the effects of Notch-1 upon LTMare through
its canonical signalling pathway. However, such studies do not rule out
the possibility that the Notch ICDs might also exert effects via other
signalling pathways, in particular the cAMP/PKA/CREB pathway, which
is known to drive neurite growth [44,45] and the expression of genes
required for LTM [17].
In support of N1ICD exerting effects on CREB an interaction between
Notch-2 and CREB1 has been reported in T-cells, which regulates the
differentiation of CD8(+) cytotoxic T lymphocytes [46]. N2ICD was
found to interact with and integrate CREB1 activity in a co-operative
manner [47], which contradicts our observations here. However, in
this reportMaekawa et al. (2008) show that theN2ICDand CREB1 inter-
action ismediated through adjacent CRE and CBF-1 DNA binding sites in
the promoter of the one gene examined, granzyme B. Our observations
suggest that N1ICD can interactwith CREB at CRE sites without the need
for adjacent CBF-1DNAbindingmotifs, as such elements are not present
in the CRE-Luc promoter used for transcriptional and chromatin immu-
noprecipitation experiments. Thus, the effects of Notch-2 and CREB
on granzyme B expression may be a special case, and the antagonistic
effects we observe here may be more generally applicable.
Most recently, with respect to Notch and memory, it has been
reported that in Drosophila full-length Notch acts in conjunction with
PKC to regulate the phosphorylation of dCREB to trigger ultradian oscilla-
tions in dCREB protein levels. This cyclical accumulation of dCREB is
proposed to be important for repetitive aspects of LTM formation, such
as memory consolidation [14].
We found that the inhibitory effect of Notch-1 on CREB is dependent
upon N1 γ-secretase cleavage, and release of the ICD from the
membrane bound receptor. This may speak to the report from Dash
et al. (2005), showing that the application of γ-secretase inhibitors
enhanced LTM [29], leading these authors to suggest that a signalling
molecule(s) generated by γ-secretase activity may have a negative
inﬂuence on long-term memory formation.
There have been consistent but incompletely understood reports
indicating there is a link between Notch signalling, the presenilins and
Alzheimer's disease, the most prevalent disorder of memory dysfunction
[48]. The familial Alzheimer's disease gene, PSEN1, is required for γ-
secretase cleavage of the Notch receptors, a processwe show is necessary
for the antagonistic effect of Notch-1 upon CRE-dependent gene
transcription. Familial mutations in PSEN1 impair Notch cleavage and
the nuclear translocation of NICDs [49], which, given NICDs regulate
CREB activity may account, at least in part, for the memory deﬁcits
Fig. 6. N1ICD represses the expression of endogenous CRE containing genes. Real time quantitative-PCR (qRT-PCR) for endogenous CRE containing genes in mouse primary neurons. a) A
forskolin time course was performed to determine the optimal time of FOS induction. b) Cultured neurons were infected with EGFP-N1ICD adenovirus (N1ICD-AD) or control β-galactosidase
(β-gal-AD) virus and treated with 10 μM forskolin as indicated. FOS, NR4A1 and SGK1 expression were determined by qRT-PCR at the time points indicated, corresponding to their peak
expression in hippocampus following CFC. N1ICD signiﬁcantly repressed the expression of each gene. Data shown are pooled values from three replica experiments. Statistical signiﬁcance
was determined by one-way ANOVA and post hoc t-testing.
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observed in mutant PSEN1 transgenic mice [49,50] and be a contributory
factor to the cognitive deﬁcits associatedwithAlzheimer's disease inman.
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